This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home
  2. IMBRUVICA®

IMBRUVICA® (ibrutinib)

Search

Search Medical Information

Please enter your specific request.

Report an AE/PQC

IMBRUVICA (ibrutinib)

IMBRUVICA (ibrutinib)

Date Last Updated: 07/15/2019

Janssen Biotech, Inc. and Pharmacyclics, Inc. entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. For medical information on IMBRUVICA (ibrutinib), please contact Pharmacyclics Medical Information at 1-877-877-3536 or email medinfo@pcyc.com.

Please view the full Prescribing Information for IMBRUVICA (ibrutinib).

Resources

Scroll to Top
Report an Adverse Event
Report a Product Quality Complaint

Who are our experts?

Pharmacists or Nurses who are specifically trained on all aspects of the Janssen products and the therapeutic areas they treat.

Need Help?

Scientific Knowledge Experts are available Monday-Friday 9am-8pm ET

1-800-JANSSEN
Email
Locate Medical
Science Liaison